NYSE · Drug Manufacturers - General · USD
Novartis AG (NVS) Stock Analysis
Novartis AG (NVS) is a Drug Manufacturers - General stock listed on NYSE and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
NVS Key Statistics
As of Oct 21, 2026Trading
- Open
- $153.12
- Previous Close
- $153.64
- Day's Range
- 152.93–154.12
- 52-Week Range
- 121.57–170.46
- Volume
- 1.02M
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.47
Valuation
- Market Cap
- $292.58B
- P/E Ratio
- 23.25
- Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
- 15.70
- PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
- 3.60
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 5.16
- EPS (ttm)Profit attributable to each share over the last twelve months.
- 6.62
Financials (FY)
- Revenue (FY)
- $56.67B+9.57%
- Net Income (FY)
- $13.98B+17.11%
- Profit marginThe share of revenue left as profit after all costs and taxes.
- 22.50%
- Shares Outstanding
- 1.90B
- 1-Year Return
- +20.77%
Dividend and dates
- Dividend
- $4.74+3.09%
- Ex-Dividend Date
- March 11, 2026
- Earnings Date
- October 27, 2026
- Avg Volume
- 1.93M
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, NVS closed at $153.93, +20.77% over 1 year.
Novartis AG (NVS) has a market capitalization of $292.58B.
In fiscal 2025, NVS reported revenue of $56.67B.
NVS Stock Return by Calendar Year
Novartis AG (NVS) 10-year return: what $10,000 became
- 1 year
- $10,000 $12,077
- +20.77%
- 5 years
- $10,000 $21,922
- +119.22%
- 10 years
- $10,000 $32,783
- +227.83%
If you had invested $10,000 in Novartis AG (NVS) 10 years ago, at the close on October 21, 2016, it would have been worth $32,783 at the close on October 21, 2026: +227.83% in total, +12.61% a year, with dividends reinvested. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | +15.05% |
| 2025 | +46.95% |
| 2024 | +0.02% |
| 2023 | +16.14% |
| 2022 | +8.06% |
| 2021 | −3.65% |
| 2020 | +3.34% |
| 2019 | +27.13% |
| 2018 | +5.95% |
| 2017 | +19.46% |
| 2016 (partial year) | −11.47% |
As of October 21, 2026.
NVS Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $56.67B | $13.98B | 24.7% |
| 2024 | $51.72B | $11.94B | 23.1% |
| 2023 | $46.66B | $14.85B | 31.8% |
| 2022 | $43.46B | $6.96B | 16.0% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $56.67B | $42.98B | $17.64B | $13.98B | 24.7% |
| 2024 | $51.72B | $38.90B | $14.54B | $11.94B | 23.1% |
| 2023 | $46.66B | $34.19B | $9.77B | $14.85B | 31.8% |
| 2022 | $43.46B | $31.88B | $7.95B | $6.96B | 16.0% |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
NVS Dividend History
Dividends per share, 2025 · 1 payments
| Year | Dividends per share | Payments | Change |
|---|---|---|---|
| 2026* | $4.77 | 1 | — |
| 2025 | $3.99 | 1 | +6.8% |
| 2024 | $3.74 | 1 | +7.8% |
| 2023 | $3.47 | 1 | +3.3% |
| Year | Dividends per share | Payments | Change |
|---|---|---|---|
| 2026 (partial year) | $4.77 | 1 | — |
| 2025 | $3.99 | 1 | +6.8% |
| 2024 | $3.74 | 1 | +7.8% |
| 2023 | $3.47 | 1 | +3.3% |
| 2022 | $3.36 | 1 | −0.6% |
| 2021 | $3.38 | 1 | +11.0% |
| 2020 | $3.04 | 1 | +18.5% |
| 2019 | $2.57 | 1 | −3.8% |
| 2018 | $2.67 | 1 | +8.4% |
| 2017 | $2.46 | 1 | — |
Most recent payment: $4.77 per share, ex-dividend March 11, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.
NVS Valuation vs Drug Manufacturers - General Median
Median of 21 stocks| Metric | NVS | Drug Manufacturers - General median | vs median |
|---|---|---|---|
| P/E | 23.25 | 25.23 | 8% below |
| P/S ratio | 5.16 | 3.23 | 60% above |
| Profit margin | 22.50% | 9.80% | 12.7 pts above |
Medians across 21 Drug Manufacturers - General stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.
Recent News
Novartis Has Five Fast-Growing Drugs, but Is Its Valuation Asking Too Much?
YahooFDA Grants Orphan Drug Designation To Novartis’ Rapcabtagene Autoleucel For Treatment Of Idiopathic Inflammatory Myopathies
BenzingaNovartis Discontinues Mid-Stage Fabhalta Trial in Lupus Nephritis for Strategic Reasons
InvestorsHubNovartis: The Sell-Off Creates An Attractive Entry Point
SeekingAlphaNovartis Discontinues Mid-Stage Lupus Trial In Latest Pipeline Setback
StocktwitsNovartis Scraps Another Drug Study. Why the Stock Is Holding Steady.
Yahoo
All 20 articles ↓Show fewer ↑
Novartis' Loss of Exclusivity Continued to Erode Entresto Sales in Q3, RBC Says
YahooWhat Is Novartis (SWX:NOVN) Signaling With Its Dual Hives Approval And MS Data?
YahooNVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido
YahooIs Novartis (SWX:NOVN) Undervalued After New MS Trial Data Took Center Stage?
YahooNovartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)
YahooFDA Greenslights Novartis's Rhapsido as First Treatment for Chronic Friction Hives
BenzingaNovartis Receives FDA Approval For Rhapsido To Treat Symptomatic Dermographism
BenzingaNovartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026
YahooNovartis (SWX:NOVN) Stock May Trade Below Fair Value As Digital CMC News Lands
YahooNovartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal
YahooStocktwits Biotech Dealmaker — Novartis, Sanofi And Novo Sign Week’s Biggest Deals
StocktwitsNovartis wagers almost $8B on a Chinese biotech’s RNA drugs
BioPharma DiveNovartis licenses Abogen mRNA autoimmune drug in $7.8B deal
QuartzNovartis Signs RNA Therapy Licensing Deal With China’s Abogen Worth Up to $7.8 Billion
InvestorsHub
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Drug Manufacturers - General Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
MRKMerck & Co., Inc.
$369.78B
AZNAstraZeneca PLC
$261.82B
AMGNAmgen Inc.
$236.98B
Popular Healthcare Stocks
UnitedHealth Group Incorporated
$374.30B
TMOThermo Fisher Scientific Inc.
$256.61B
GILDGilead Sciences, Inc.
$190.42B
ABTAbbott Laboratories
$173.92B
NVONovo Nordisk A/S
$172.38B